Hangzhou Biotest Biotech Co Ltd
SSE:688767
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.4), the stock would be worth ¥22.05 (36% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.2 | ¥34.33 |
0%
|
| 3-Year Average | 1.4 | ¥22.05 |
-36%
|
| 5-Year Average | 1.6 | ¥25.67 |
-25%
|
| Industry Average | 4.2 | ¥65.2 |
+90%
|
| Country Average | 2.4 | ¥38.35 |
+12%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
H
|
Hangzhou Biotest Biotech Co Ltd
SSE:688767
|
5.1B CNY | 2.2 | 50 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
349.5B USD | -106.9 | 83.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
183B USD | 21.1 | 23.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
160.4B USD | 7.1 | 18.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 5.9 | 27.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.3B USD | 2.5 | 17.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 6.6 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 2.2 | 30 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.4 |
| 70th Percentile | 3.9 |
| Max | 1 172 445.9 |
Other Multiples
Hangzhou Biotest Biotech Co Ltd
Glance View
Hangzhou Biotest Biotech Co., Ltd. engages in the research and development, production and sales of point-of-care testing (POCT) diagnostic reagents. The company is headquartered in Hangzhou, Zhejiang and currently employs 622 full-time employees. The company went IPO on 2021-09-08. The firm's products include reproductive health testing series, such as human chorionic gonadotropin testing reagent and luteinizing hormone testing reagent, and drug abuse testing series, such as morphine testing reagent and cocaine testing reagent, and infectious disease testing series, such as adenovirus testing reagent and typhoid antibody testing reagent, and tumor marker testing series, such as alpha fetoprotein detection reagent, and myocardial marker detection series, such as dimer detection reagent and myocardial series detection reagent.
